GLP-1 injection pen technique: What the science actually says

What did @suzannecarepharmacy actually say?

A nurse practitioner walked viewers through using a brand-name GLP-1 autoinjector pen, covering the color-coded cap system, the lock/unlock mechanism, injection site prep, and how to interpret the two audible clicks that signal dose delivery. The advice was framed for first-time users who are nervous about self-injecting.

The creator described a pen with a "purple side" for the button and a "gray side" where the needle sits under a cap. She explained unlocking the device only when ready, pressing it firmly against clean skin, and listening for two clicks, with the second click confirming the medication has been administered. She closed by recommending the user hold the pen in place "for like a few seconds after" before removing it. The video ended with her calling the injection a "DLP1" injection, which appears to be a verbal slip rather than a new drug category.

Does the science back this up?

The core injection technique described here is consistent with manufacturer instructions and clinical guidance. The two-click confirmation system is a real feature of autoinjector pens, and the advice to hold the pen against the skin briefly after the second click is supported by prescribing information for both semaglutide and tirzepatide products.

The FDA-approved prescribing information for Wegovy and Ozempic (Novo Nordisk) and for Mounjaro and Zepbound (Eli Lilly) all specify that users should hold the pen against the skin for a set number of seconds after activation to ensure full dose delivery. Some devices specify six seconds, others up to ten. A 2022 review by Whicher et al. in Diabetes Therapy noted that injection technique errors, including premature pen removal, are a documented source of subtherapeutic dosing in GLP-1 therapies. The lock mechanism described, present on several autoinjector designs, is a legitimate safety feature to prevent accidental activation.

What did they get wrong (or right)?

Mostly right on technique, with one meaningful gap: she never told viewers how long to hold the pen after the second click. "A few seconds" is vague in a way that could matter.

The prescribing information for semaglutide pens specifies holding for six seconds post-click. For tirzepatide pens, Eli Lilly's instructions specify holding the pen firmly for ten seconds. Saying "a few seconds" undersells that specificity. If someone pulls the pen at three seconds, they may not get the full dose. That is not a trivial error when these medications cost hundreds of dollars per injection and are titrated carefully.

What she got right: the alcohol swab prep step, the three valid injection sites (abdomen, upper arm, thigh), and the lock/unlock sequence are all consistent with manufacturer guidance. Reminding users to wait until the pen is against the skin before unlocking is a genuinely useful safety tip that reduces the risk of accidental needle exposure. The overall framing is calm and practical, which has real value for injection-anxious patients.

• Accurate: Two-click confirmation system
• Accurate: Injection site options and alcohol prep
• Accurate: Lock/unlock safety sequence
• Vague: Hold duration after second click, device-specific guidance omitted
• Minor verbal slip: "DLP1" instead of GLP-1 at the end

What should you actually know?

The hold-time detail is not pedantic. It is the difference between a full dose and a partial one, and it varies by device. Check your specific pen's instructions.

Every autoinjector pen for GLP-1 medications comes with a patient instruction leaflet, and the steps are device-specific. A Wegovy pen does not behave identically to a Zepbound pen. The general sequence described in this video is a reasonable starting framework, but it should not replace reading the instructions for your specific device. If you were prescribed a compounded semaglutide or tirzepatide, note that compounded versions typically come as vials with separate syringes, not autoinjector pens, and the administration process is entirely different. This video applies only to brand-name autoinjector formats.

If you are genuinely nervous about self-injection, most prescribing clinicians or pharmacies can walk you through a demo before your first dose. A 2021 patient adherence study by Hoogenberg et al. in Patient Preference and Adherence found that structured injection training significantly reduced technique errors and increased patient confidence in GLP-1 self-administration. A three-minute TikTok is a useful supplement, not a replacement, for that conversation.